SLC3A2 and central nervous system cancer: While LAT1 could serve as a more appropriate marker for glioblastoma stem cells (GSC) compared with CD98hc, the aggressiveness and malignancy of CD98+ glioma cells can significantly be reduced by suppressing CD98 expression [61].